Peptides derived from NY-ESO-1 have been employed in phase I clinicaltrials for prostate cancer vaccines.41 Themost immunogenic peptides (restricted by HLA-A*02 and specific haplotypes)were employed, specifically DP4-restricted NY-ESO-1 peptide YGRKKRRQRRRSLLMWITQAFLPV,DR4-restricted NY-ESO-1 peptide PGVLLKEFTVSG (ESO DR4-1P), andthe A2-restricted peptide SLLMWITQC (fragment NY-ESO-1 157–165).41 This evidence concerns the gene HLA-A and prostate carcinoma.